

FINANCIAL RESULTS
for full year
2022

21/02/2023



KEY FIGURES

Summary

IN € MILLIONS	2022	2021	Growth	% Growth
Operating revenue	817.7	648.7	169.0	26%
Gross profit	518.9	386.2	132.7	34%
EBITDA	278.9	202.9	76.0	37%
EBIT	256.0	181.6	74.5	41%
Net profit	199.7	153.1	46.6	30%
Capital Expenditure	51.4	40.9	10.4	26%
FCF	186.3	108.6	77.7	72%
Gross profit as % of revenue	63.5%	59.5%		3.9 p.p
EBITDA as % of revenue	34.1%	31.3%		2.8 p.p
EBIT as % of revenue	31.3%	28.0%		3.3 p.p
Net profit as % of revenue	24.4%	23.6%		0.8 p.p
Capex as % of revenue	6.3%	6.3%		0.0 p.p
FCF as % of revenue	22.8%	16.7%		6.0 p.p
	As of Dec. 31, 2022	As of Dec. 31, 2021	Growth	% Growth
Net debt (€m)	(54.2)	(27.4)	(26.8)	98%

Note: certain numerical figures included in this document have been rounded. Therefore, discrepancies in tables between totals and the sums of the amounts listed may occur due to such rounding.

The consolidated financial statements of Grupo ROVI for 2022 and the comparative information for 2021 (balance sheet, consolidated income statement and cash flow statement) are attached to this report (see Appendix 1).

CONTENTS


HIGHLIGHTS FY 2022	3
GROUP MANAGEMENT REPORT	6
INCOME STATEMENT	6
REVENUES	6
SPECIALTY PHARMACEUTICAL BUSINESS	8
LOW MOLECULAR WEIGHT HEPARINS	9
OTHER PRESCRIPTION-BASED PHARMACEUTICAL PRODUCTS	10
CONTRAST AGENTS AND OTHER HOSPITAL PRODUCTS	11
CONTRACT MANUFACTURING ORGANISATION (“CMO”) BUSINESS	11
OTHER INCOME	12
COSTS	12
GROSS PROFIT	12
RESEARCH AND DEVELOPMENT EXPENSES	12
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	12
DEPRECIATION	13
NET FINANCE RESULT	13
EFFECTIVE TAX RATE	13
FINANCIAL PERFORMANCE	13
DIVIDEND	15
FINANCIAL POSITION	15
LIQUIDITY	18
OUTLOOK	21
R&D UPDATE	22
ESG	23
KEY OPERATING AND FINANCIAL EVENTS	24
APPENDIX 1	

HIGHLIGHTS FY 2022


ROVI REPORTS OPERATING REVENUE GROWTH OF 26% AND EBITDA GROWTH OF 37%

- Operating revenue increased by 26% to 817.7 million euros driven by (i) the strength of the contract manufacturing organization (“CMO”) business, which grew by 52%, and (ii) the specialty pharmaceutical business, where sales rose 8%.
- Sales of the heparin franchise (Low Molecular Weight Heparins (LMWH) and other heparins increased by 9% to 264.0 million euros. Sales of the enoxaparin biosimilar increased 23% to 152.9 million euros.
- EBITDA increased by 37% to 278.9 million euros.
- Net profit increased by 30% to 199.7 million euros.
- Launch of Okedi® (Risperidone ISM®) in Germany (April 2022), United Kingdom (July 2022) and Spain (September 2022) for the treatment of schizophrenia in adults.
- On October 4th, 2022, ROVI presented Glycopepton Biotech, S.L., a joint venture with Càrniques Celrà, S.L. and Grupo Empresarial Costa, S.L., that involves the creation of one of the first national structures for self-sufficiency in heparins. The project involves the construction of a facility at the Industrial Logistics Platform of Fraga (Huesca), which will produce compounds of high biological value that derive from the intestinal mucosa of pigs.
- ROVI’s ESG aspects have been evaluated by Sustainalytics, having obtained an “ESG Risk Rating 2021” of 17.3, which places the company at low risk (between 10 and 20). ROVI has attained the first position out of 458 companies in the sub-industry “pharmaceuticals”.
- ROVI will propose to the General Shareholders' Meeting a dividend of 1.2938 euros per share charged to the 2022 profit and retained earnings. This proposed dividend would mean an increase of 35% on the dividend charged to the 2021 profit (€0.9556/share) and represents 35% of the net profit for 2022 attributed to the parent company.

REVENUE BY REGION (%)



REVENUE BY BUSINESS UNIT (€Mn)



OUTLOOK

At the end of 2022, ROVI exceeded the higher end of its operating revenue guidance range (15% - 20%), standing at 26%.

For 2023, ROVI expects its operating revenue to show low-double-digit negative growth on 2022, although a positive growth of between 5% and 10% is expected in comparison with the 2021 figure.

For 2023, ROVI is assuming a new post-pandemic scenario in which COVID-19 would foreseeably be a seasonal disease and, in principle, the vaccine would be administered once a year. For this reason, ROVI expects a stronger second half of the year compared to the first half regarding the CMO business. The first quarter of 2023 is expected to include revenues linked to the production of vaccines in the fourth quarter of 2022 but the second quarter of 2023 is expected to be the lowest quarter in terms of CMO sales.

Nevertheless, the uncertainty related to the evolution of the disease is very high. It is not, therefore, possible to make a precise assessment of the impact that this new scenario could have on its CMO business. Likewise, under the terms of the agreement signed with Moderna in February 2022, ROVI is still investing in increasing the compounding, aseptic filling, inspection, labelling and packaging capacities at its facilities and expects them to be fully installed at the end of 2024.

Taking account of the aforementioned guidance on a decrease in operating revenue in 2023, as well as the fact that ROVI will continue with its investment policy as stated, it is reasonable to expect that the Company's profits may also see a downward adjustment in 2023.



Juan López-Belmonte Encina, Chairman and Chief Executive Officer of ROVI, said: "We are very excited about the launch of Okedi®, a 4-weekly Risperidone LAI based on our ISM® technology for the treatment of schizophrenia, which took place in Germany in April, in UK in July and in Spain in September. This launch consolidates our internationalization strategy as one of our pillars of future growth. Likewise, we are currently undergoing a regulatory process in the United States to obtain the marketing authorization of this product. We also obtained positive results in our Phase I study for another candidate, Letrozole ISM®, and made significant progress in our quarterly Risperidone formulation, reflecting our clear commitment to our ISM® technology, which is expected to be the company's growth engine in the future. Since the first COVID-19

vaccines were launched in December 2020, ROVI as a manufacturer of the Moderna vaccine, has been a fundamental pillar in providing a swift, flexible, and effective response to take the COVID-19 vaccine to all corners of the planet. 2022 demonstrate our company's ability to continuously adapt, compete and excel. We have managed to exceed our guidance both in operating revenue and CMO business. We achieved 26% operating revenue growth, mainly driven by the strength of the contract manufacturing organization ("CMO") business, which grew by 52% and by the specialty pharmaceutical business, where sales rose 8%. We forecast continued growth thanks to our enoxaparin biosimilar, which grew by 23% and was already marketed in 38 countries in 2022. We are in a phase of international expansion and our enoxaparin biosimilar will enable us to be present in more than 110 countries in the long term. We are very excited about the potential of our LMHW franchise and aspire to become a benchmark player in this field worldwide. Likewise, we are investing to become self-sufficient in obtaining crude and sodium heparin in order to be present in all the manufacturing phases of LMWHs. We expect this investment to help us to increase the future margins of the heparin division. Furthermore, we expect our specialty business in Spain, supported by a good performance by products such as Neparvis®, from Novartis, and Volutsa®, from Astellas, to provide us with a sustainable and profitable growth opportunity in the future. Finally, (i) the agreement signed with Moderna and (ii) the reorientation of the contract manufacturing activities strategy towards high-value-added products, backed by the high degree of technological specialization of our plants in differentiated niches, enabled our CMO business to increase 52% in 2022".

GROUP MANAGEMENT REPORT

for the annual period ending December 31st, 2022

INCOME STATEMENT

IN € MILLIONS	2022	2021	Growth	% Growth
Operating revenue	817.7	648.7	169.0	26%
Other income	2.1	1.3	0.8	58%
Total revenue	819.8	650.0	169.8	26%
Cost of goods sold	(300.9)	(263.9)	(37.1)	14%
Gross profit	518.9	386.2	132.7	34%
% margin	63.5%	59.5%		3.9 pp
R&D expenses	(23.9)	(27.4)	3.6	-13%
SG&A	(216.3)	(156.0)	(60.3)	39%
Share of profit of a joint venture	0.2	0.2	0.0	9%
EBITDA	278.9	202.9	76.0	37%
% margin	34.1%	31.3%		2.8 pp
EBIT	256.0	181.6	74.5	41%
% margin	31.3%	28.0%		3.3 pp
Finance Income/(Costs)	1.9	1.1	0.9	82%
Profit before income tax	258.0	182.6	75.3	41%
Income tax	(58.3)	(29.6)	(28.8)	97%
Effective tax	22.6%	16.2%		6.4 pp
Net profit	199.7	153.1	46.6	30%
Net profit attributable to parent company	199.7	153.1	46.6	30%
Profit attributable to minority interests	0.0	–	0.0	n.a.

REVENUES

Total revenue by business unit

IN € MILLIONS	2022	2021	Growth	% Growth
Specialty pharmaceutical business	414.2	384.0	30.2	8%
CMO business	403.5	264.7	138.9	52%
Operating revenue	817.7	648.7	169.0	26%
Other income	2.1	1.3	0.8	58%
Total revenue	819.8	650.0	169.8	26%

Operating revenue increased by 26% to 817.7 million euros in 2022, driven by the strength of the contract manufacturing organisation business, which grew by 52%, and by the specialty pharmaceutical business, where sales rose 8%. **Total revenue** increased by 26% to 819.8 million euros in 2022.

Sales outside Spain increased by 41% to 553.4 million euros in 2022, 82.6 million euros (or 15%) of which related to international subsidiaries, mainly due to (i) the increase in LMWH international sales and (ii) the increase in the contract manufacturing organisation business. Sales outside Spain represented 68% of operating revenue in 2022 compared to 60% in 2021.

SPECIALTY PHARMACEUTICAL BUSINESS

Sales of the specialty pharmaceutical business

IN € MILLIONS	2022	2021	Growth	% Growth
Prescription-based pharmaceutical products	372.6	347.4	25.2	7%
LMWH franchise	256.6	234.8	21.9	9%
Biosimilar of enoxaparin	152.9	124.0	28.8	23%
Bemiparin (Hibor)	103.8	110.7	(6.9)	-6%
Sales in Spain	66.9	69.4	(2.6)	-4%
International sales	36.9	41.3	(4.4)	-11%
Neparvis	39.1	38.5	0.6	2%
Volutsa	17.8	16.3	1.5	9%
Vytorin & Absorcol & Orvatez	32.1	28.3	3.7	13%
Other products	36.0	41.4	(5.4)	-13%
Okedi	2.0	-	2.0	n.a.
Discounts to the National Health System	(11.0)	(11.9)	0.9	-8%
Contrast agents and other hospital products	40.1	35.5	4.6	13%
Other products	1.5	1.1	0.3	31%
Total specialty pharmaceutical business	414.2	384.0	30.2	8%

Sales of **prescription-based pharmaceutical** products rose 7% to 372.6 million euros in 2022.

Sales of the **heparin franchise** (Low Molecular Weight Heparins and other heparins) increased by 9% to 264.0 million euros in 2022. Heparin sales represented 32% of operating revenue in 2022 compared to 37% in 2021.

Heparin franchise

IN € MILLIONS	2022	2021	Growth	% Growth
LMWH franchise	256.6	234.8	21.9	9%
Biosimilar of enoxaparin	152.9	124.0	28.8	23%
Bemiparin (Hibor)	103.8	110.7	(6.9)	-6%
Sales in Spain	66.9	69.4	(2.6)	-4%
International sales	36.9	41.3	(4.4)	-11%
Other heparins ¹	7.3	7.3	0.1	1%
Heparins franchise	264.0	242.0	22.0	9%

LOW MOLECULAR WEIGHT HEPARINS

Sales of **Low Molecular Weight Heparins** (LMWH) (Enoxaparin biosimilar and Bemiparin) increased by 9% to 256.6 million euros in 2022.

Sales of the **Enoxaparin biosimilar** increased 23% to 152.9 million euros in 2022 mainly because of (i) the launch of the product in five new countries during 2022 and (ii) the increase in the demand for the product in countries where we are already present. ROVI commenced the marketing of its Enoxaparin biosimilar in Germany in 2017; in UK, Italy, Spain, France, Austria, Latvia and Estonia in 2018; in Portugal, Poland, Costa Rica, Finland, and Sweden in 2019; in South Africa, Israel, Peru, Holland, Panama, and the Dominican Republic in 2020; in Canada, Belgium, Malaysia, Albania, North Macedonia, Guatemala, El Salvador, Honduras, Georgia, Bahamas, Jamaica, Gabon, Democratic Republic of Congo, and Trinidad and Tobago in 2021; and in Brazil, Luxembourg, Colombia, Bosnia and Herzegovina and Kosovo in 2022.

Bemiparin sales decreased 6% to 103.8 million euros in 2022. International sales of Bemiparin decreased by 11% to 36.9 million euros. This decrease was mainly linked to the decrease in sales in the Turkish and Russian markets. Sales of Bemiparin in Spain (Hibor®) decreased 4% to 66.9 million euros in 2022, mainly due to a lower penetration of the product in the prophylaxis segment.

On October 4, 2022, ROVI presented Glicopepton Biotech, S. L., a joint venture with Càrniques Celrà, S.L. and Grupo Empresarial Costa, S.L. that involves the creation of one of the first national structures for self-sufficiency in heparins and products of high nutritional value to be used in the composition of animal feed and fertilisers.

The project involves the construction of a facility at the Industrial Logistics Platform of Fraga (Huesca), which will produce compounds of high biological value that derive from the intestinal mucosa of pigs. It will involve a joint investment of approximately 40

¹ Other heparins are reported in the "Contrast agents and other hospital products" line.

million euros over the next four years and is expected to create around 30 direct skilled jobs. The project will be subject to obtaining the applicable administrative and regulatory permits and authorisations.

ROVI has in-house production capacity to transform raw heparin into sodium heparin and intends to expand this capacity through the construction of a new sodium heparin production line (already underway), in order to be present in all the manufacturing phases of low-molecular-weight heparins.

OTHER PRESCRIPTION-BASED PHARMACEUTICAL PRODUCTS

Sales of **Neparvis®**, a specialty product from Novartis, launched in Spain in December 2016, indicated for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction, increased 2% year on year to 39.1 million euros in 2022, compared to 38.5 million euros in 2021.

Sales of **Volutsa®**, a specialty product from Astellas Pharma indicated for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia, launched in Spain in February 2015, increased by 9% to 17.8 million euros in 2022.

Sales of **Vytorin®**, **Orvatez®** and **Absorcol®**, specialty products from Merck Sharp & Dohme ("MSD") indicated as adjunctive therapy to diet in patients with hypercholesterolemia, increased 13% to 32.1 million euros in 2022. ROVI ceased to distribute Absorcol® as of 31 December 2022 and Vytorin® as of 31 January 2023. Sales of Absorcol® and Vytorin® represented 24% of total hypercholesterolemia product sales in 2022.

Sales of **Okedi®**, the first ROVI product based on its leading-edge drug delivery technology, ISM®, for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone, reached an amount of 2.0 million euros in 2022. It was launched in Germany in April, in UK in July and in Spain in September 2022.

In Germany, access to doctors is accelerated in the fourth quarter of 2022, where sales multiplied by 2.1 compared to the previous quarter of the same year, and the product was received very positively in the medical education activities ROVI carried out. In the United Kingdom, the product is in the introduction phase in the "trusts" (entities that manage the health areas). Subsequently, it will be introduced in the hospitals managed by each "trust" and it is expected that it will soon become available in most hospital pharmacies. In Spain, the introduction of the product in the regions and hospitals is progressing swiftly and, at the end of 2022, it was already available in the 100% of the autonomous communities.

According to IQVIA, Spanish innovative product market increased by 4% in 2022 compared to last year. Nevertheless, ROVI prescription-based pharmaceutical product sales increased 7% in 2022, outperforming the market by 3 percentage points.

In 2022, ROVI signed a new agreement with Merck Sharp and Dohme (MSD), to promote and distribute Xelevia® (sitagliptin) and Velmetia® (sitagliptin and metformin) in Spain. The marketing of both products began in January 2023 for a period of 3 years, renewable annually.

Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The metformin and sitagliptin combination is used to treat high blood sugar levels caused by type 2 diabetes. Metformin reduces the absorption of sugar from the stomach, reduces the release of stored sugar from the liver, and helps your body use sugar better.

In 2022, ROVI signed a new agreement with Teva Pharma S.L.U. to promote and distribute Baceq® (paliperidone) in Spain, a monthly injectable generic medicine corresponding to Xeplion® of Janssen Pharmaceuticals and indicated for maintenance treatment of adult schizophrenia patients stabilised with paliperidone or risperidone. ROVI's hospital line is responsible for promoting this product in the hospital segment. Marketing of this product commenced in January 2023 for a period of ten years.

Thus, ROVI is seeking a prominent position in the psychiatry area by including a once-monthly injectable generic alternative on its portfolio, thus contributing to the sustainability of the public health system.

According to IQVIA data, in the twelve months up to December 2022 (MAT December 2022), the injectable antipsychotic market in Spain totalled 283.8 million euros. In the same period, the medicine Xeplion® held a 30% share of the injectable antipsychotic market in Spain.

CONTRAST AGENTS AND OTHER HOSPITAL PRODUCTS

Sales of **contrast imaging agents and other hospital products** increased by 13% to 40.1 million euros in 2022. This increase shows the strong recovery of the Spanish and Portuguese hospital activity during this period after the effects of lockdowns during the pandemic.

CONTRACT MANUFACTURING ORGANISATION (“CMO”) BUSINESS

CMO sales increased by 52% to 403.5 million euros in 2022 because of (i) the booking of the income related to the production of the COVID-19 vaccine, (ii) the booking of the income related to the activities to prepare the plant for the COVID-19 vaccine production under the agreement with Moderna, and (iii) the reorientation of our contract manufacturing activities strategy towards high-value-added products.

The growth achieved in 2022 surpassed by 12 percentage points the higher end of the range of between 30% and 40% published when the company released its 2021 results.

OTHER INCOME

Other income (subsidies) increased by 58% to 2.1 million euros in 2022, compared to the year 2021.

COSTS

GROSS PROFIT

Gross profit increased by 34% to 518.9 million euros in 2022. Gross margin showing an increase of 3.9 percentage points, from 59.5% in 2021 to 63.5% in 2022. This increase is mainly due to the increase in the CMO business that contributes higher margins to the Group sales. This positive impact on the gross margin offset the increase in the LMWH cost of goods sold in 2022 compared to the year 2021.

RESEARCH AND DEVELOPMENT EXPENSES

R&D expenses decreased 13% to 23.9 million euros in 2022. They were mainly related to (i) preparing the development of the phase II of Letrozole ISM® and (ii) the development of a new formulation of Risperidone ISM® for a 3-monthly injection.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

SG&A expenses increased 39% to 216.3 million euros in 2022 mainly as a result of (i) an increase in expenses related to the manufacture of the Moderna vaccine; (ii) an increase of 5.4 million euros in the energy cost; and (iii) an increase in expenses due to the Okedi® launch in Europe.

SG&A expenses

IN € MILLIONS	2022	2021	Growth	% Growth
Employee benefit expenses (exc. R&D)	97.3	81.4	15.9	19%
Other operating expenses (exc. R&D)	119.0	74.5	44.5	60%
Total SG&A expenses	216.3	156.0	60.3	39%
Expenses related to international subsidiaries	19.2	10.5	8.7	82%

DEPRECIATION

Depreciation and amortisation expenses increased by 7% to 22.9 million euros in 2022, as a result of the new property, plant and equipment and intangible assets purchases made during the last twelve months.

NET FINANCIAL INCOME


Net financial income increased 82% to 1.9 million euros in 2022 mainly due to higher returns on financial investments. This income was partially offset by lower income related to exchange-rate derivative financial instruments and higher negative exchange differences.

EFFECTIVE TAX RATE

The **effective tax rate** was 23% in 2022, compared to 16% in 2021, mainly due to the increase of the profit before income tax.

FINANCIAL PERFORMANCE

Million euros



EBITDA

EBITDA increased to 278.9 million euros in 2022, a rise of 37% compared to the previous year. This positive result reflects a 2.8 percentage point increase in the EBITDA margin, which was up to 34.1% in 2022 from 31.3% in 2021.

EBIT

EBIT increased by 41% to 256.0 million euros in 2022, reflecting a 3.3 percentage point rise in the EBIT margin, which was up to 31.3% in 2022 from 28.0% in 2021.

NET PROFIT

Net profit increased by 30%, from 153.1 million euros in 2021 to 199.7 million euros in 2022.

Non-controlling interests refer to ROVI's partners in Glicopepton Biotech, S. L. (see page 25).

PRE-R&D/FLAT R&D

EBITDA “Pre-R&D”, calculated excluding R&D expenses, increased by 31%, from 230.4 million euros in 2021 to 302.8 million euros in 2022, reflecting a 1.5 percentage point increase in the EBITDA margin to 37.0% in 2022 (see “Pre-R&D costs” columns of the table below). Likewise, recognising the same amount of R&D expenses in 2022 as in 2021, EBITDA would have increased by 36% to 275.3 million euros, reflecting a 2.4 percentage point increase in the EBITDA margin to 33.7% in 2022, up from 31.3% in the previous year (see “Flat R&D costs” columns of the table below).

EBIT “pre-R&D”, calculated excluding R&D expenses, increased by 34%, from 209.0 million euros in 2021 to 279.9 million euros in 2022, reflecting a 2.0 percentage point increase in the EBIT margin to 34.2% in 2022 (see “Pre-R&D costs” columns of the table below). Likewise, recognising the same amount of R&D expenses in 2022 as in 2021, EBIT would have increased by 39% to 252.5 million euros, reflecting a 2.9 percentage point rise in the EBIT margin to 30.9% in 2022, up from 28.0% in 2021 (see “Flat R&D costs” columns of the table below).

Net profit “pre-R&D”, calculated excluding R&D expenses, increased by 24%, from 176.1 million euros in 2021 to 218.1 million euros in 2022 (see “Pre-R&D costs” columns of the table below). Likewise, recognising the same amount of R&D expenses in 2022 as in 2021, net profit would have increased by 29% to 196.9 million euros (see “Flat R&D costs” columns of the table below).

Pre-R&D/Flat R&D

IN € MILLIONS	Reported		Pre-R&D costs			Flat R&D costs		
	2022	2021	2022	2021	% Growth	2022	2021	% Growth
Operating revenue	817.7	648.7	817.7	648.7	26%	817.7	648.7	26%
Other income	2.1	1.3	2.1	1.3	58%	2.1	1.3	58%
Total revenue	819.8	650.0	819.8	650.0	26%	819.8	650.0	26%
Cost of sales	(300.9)	(263.9)	(300.9)	(263.9)	14%	(300.9)	(263.9)	14%
Gross profit	518.9	386.2	518.9	386.2	34%	518.9	386.2	34%
% margin	63.5%	59.5%	63.5%	59.5%	3.9 pp	63.5%	59.5%	3.9 pp
R&D expenses	(23.9)	(27.4)	0.0	0.0	n.a.	(27.4)	(27.4)	n.a.
SG&A	(216.3)	(156.0)	(216.3)	(156.0)	39%	(216.3)	(156.0)	39%
Share of profit of a joint venture	0.2	0.2	0.2	0.2	9%	0.2	0.2	9%
EBITDA	278.9	202.9	302.8	230.4	31%	275.3	202.9	36%
% margin	34.1%	31.3%	37.0%	35.5%	1.5 pp	33.7%	31.3%	2.4 pp
EBIT	256.0	181.6	279.9	209.0	34%	252.5	181.6	39%
% margin	31.3%	28.0%	34.2%	32.2%	2.0 pp	30.9%	28.0%	2.9 pp
Net profit	199.7	153.1	218.1	176.1	24%	196.9	153.1	29%
% margin	24.4%	23.6%	26.7%	27.1%	-0.5 pp	24.1%	23.6%	0.5 pp

DIVIDEND

ROVI General Shareholders Meeting, on 14 June 2022, approved the payment of a gross dividend of 0.9556 euros per share on 2021 earnings; it means an increase of 151% compared to the dividend on 2020 earnings (€0.3812/share) and represents a 35% pay out. This dividend was paid on 7 July 2022.

ROVI's Board of Directors will put a proposal to the Ordinary General Meeting for distribution of a dividend of 69,886,103.93 euros, equivalent to 1,2938 euros per share entitled to receive it. This represents a 35% increase on the dividend charged to the 2021 profit (€0.9556/share) and entails the distribution of a sum equivalent to approximately 35% of the 2022 consolidated net profit attributed to the parent company, broken down as follows:

- Application of profit: the entire profit of Laboratorios Farmacéuticos ROVI, S.A. for 2022, 39,116,103.39 euros, will be applied to the dividend distribution; and
- Additionally, a proposal will be made to distribute a further 30,770,000.54 euros as dividends charged to the freely available reserves accounted for as "Retained earnings".

FINANCIAL POSITION

Balance Sheet

IN € MILLIONS	Dec. 31, 2022	Dec. 31, 2021	Growth	% Growth
Assets				
Non-current assets	255.6	226.3	29.3	13%
Current assets	623.1	506.4	116.7	23%
Total assets	878.7	732.7	146.0	20%
Equity	521.4	471.0	50.4	11%
Liabilities				
Non-current liabilities	63.4	71.3	(7.9)	-11%
Financial debt	59.4	66.7	(7.3)	-11%
Current liabilities	293.9	190.4	103.5	54%
Financial debt	12.7	6.4	6.3	98%
Total liabilities	357.3	261.7	95.6	37%
Total equity and liabilities	878.7	732.7	146.0	20%

TOTAL ASSETS

ROVI's **total assets** increased by 20% from 732.7 million euros as of December 31, 2021 to 878.7 million euros as of December 31, 2022, mainly due to (i) an increase in property plant and equipment of 33.8 million euros in 2022 and (ii) an increase in inventories of 66.5 million euros in 2022 mainly due to the increase in heparin stock.

As of December 31, 2022, **Social Security and Public Administrations total debt** with ROVI amounted to 14.6 million euros, from 9.0 million euros as of December 31, 2021, of which 8.7 million euros in Spain, 1.2 million euros in Portugal and 4.7 million euros in Italy.

EQUITY

ROVI's **equity** increased by 50.4 million euros to 521.4 million euros as of December 31, 2022. This increase resulted from the "profit of the year".

TOTAL LIABILITIES

ROVI's total **liabilities** increased by 37% from €261.7 million as of December 31, 2021 to €357.3 million as of December 31, 2022, mainly due to (i) an increase in the "contract liabilities" item of 57.4 million euros, which mainly related to amounts billed to customers that had not yet been taken to profit and loss as service revenue as of December 31, 2022 and (ii) a rise of 40.6 million euros in the "trade and other payables" caption.

As of December 31, 2022, ROVI **total debt** increased to 72.2 million euros. Debt with public administration, which is 0% interest rate debt, represented 14% of total debt as of December 31, 2022.

Total Debt

IN € THOUSANDS	Dec 31, 2022	Dec 31, 2021	Interest rate
Bank borrowings	44,107	44,821	0.68-2.09
Debt with public administration	10,175	10,661	0
Financial liabilities for leases	17,856	17,663	-
Derivative financial instruments	28	17	-
Total	72,166	73,162	

As of December 31, 2022, bank borrowings decreased by 0.7 million euros. In December 2017, ROVI announced the European Investment Bank (EIB) had granted it a loan to support its investments in Research, Development and Innovation. The loan was for 45 million euros. As of December 31, 2022, ROVI had drawn 45 million euros against this credit line; 5 million euros at a variable interest rate of Euribor at 3 months + 0.844% (the latest interest rate paid was 2.092% in January 2023) and 40 million euros at a fixed interest of 0.681%. Repayment of the variable interest loan started in October 2021 (quarterly repayments) and its current outstanding balance is 4.1 million euros. The credit at a variable interest matures in 2028 and the credit at a fixed interest matures in 2029, both includes a grace period of 3 years.


In July 2022, ROVI announced that the European Investment Bank (EIB) had granted it a new loan to support its investments in Research, Development and Innovation. The loan is for 50 million euros with a repayment period of 10 years, has a three-year grace period, and may be drawn down over a term of two years.

GROSS CASH POSITION AND NET DEBT

As of December 31, 2022, ROVI had a gross cash position of 126.4 million euros, compared to 100.5 million euros as of December 31, 2021, and net cash of 54.2 million euros (equity securities plus deposits plus financial derivatives plus cash and cash equivalents minus current and non-current financial debt), compared to 27.4 million euros as of December 31, 2021.

Net cash generated in operating activities amounted to 237.6 million euros in 2022, compared to 149.4 million euros in 2021. Net cash generated from operating activities excluding changes in working capital increased 39% to 294.3 million euros in 2022 from 211.7 million euros in 2021.

Million euros



LIQUIDITY

Cash Flow

IN € MILLIONS	2022	2021	Growth	% Growth
Cash flow from operating activities	237.6	149.4	88.2	59%
Cash flow from investing activities	(57.2)	(40.8)	(16.3)	40%
Cash flow from financing activities	(154.5)	(62.7)	(91.8)	146%
Net increase/ (decrease) in cash	25.9	45.9	(20.0)	-44%
Cash at the beginning of the period	99.0	53.2	45.9	86%
Cash at the end of the period	124.9	99.0	25.9	26%

CASH FLOW FROM OPERATING ACTIVITIES

Cash flow from operating activities increased to 237.6 million euros in 2022 from 149.4 million euros in 2021. This increase was mainly due to:

- the increase of 75.3 million euros in profit before income tax;
- the booking of 57.1 million euros under the “Proceeds from CMO services” caption in 2022 relating to payments received but not yet allocated to the income statement, compared to the 34.4 million euros recognized in 2021;
- the decrease of 26.8 million euros in the “trade and other receivables” caption in 2022 compared to a decrease of 74.2 million euros in 2021; and
- the increase of 41.7 million euros in the “trade and other payables” item in 2022, compared to an increase of 35.4 million euros in 2021.

These positive impacts were partially offset by:

- the decrease of 71.6 million euros in the “inventory” item in 2022 compared to a decrease of 23.4 million euros in 2021; and
- the outflow of 43.9 million euros in the “income tax cash flow” item in 2022 compared to an outflow of 23.9 million euros in this caption in 2021.

CASH FLOW FROM INVESTING ACTIVITIES

ROVI invested 51.4 million euros in 2022, compared to 40.9 million euros in 2021.

Capital expenditure

IN € MILLIONS	2022	2021	Growth	% Growth
Madrid Injectable plant	2.1	2.9	(0.7)	-26%
San Sebastián de los Reyes plant	3.0	2.0	1.0	52%
Granada plant	0.7	1.4	(0.7)	-52%
Alcalá de Henares plant	3.4	4.2	(0.9)	-21%
Expenditure on maintenance and other capex	2.6	3.3	(0.7)	-20%
Maintenance Capex	11.8	13.8	(2.0)	-14%
ISM industrialisation	6.7	5.5	1.3	23%
Escúzar plant	13.8	18.8	(5.0)	-27%
Glicopeptón	1.9	-	1.9	n.a.
New filling lines and operations expansion	17.2	2.9	14.2	n.a.
Investment Capex	39.6	27.2	12.4	46%
Total Capex	51.4	40.9	10.4	26%

CASH FLOW FROM FINANCING ACTIVITIES

Cash flow from financing activities increased to 154.5 million euros in 2022 from 62.7 million euros in 2021. This increase was mainly attributable to ROVI's share buy-back programmes executed in 2022, amounting to 135.0 million euros, and to the dividend paid in July 2022, which was 51.0 million euros, compared to the 21.1 million euro dividend paid in July 2021.



Javier López-Belmote Encina, Deputy Chairman and Chief Financial Officer of ROVI, said *“We are very happy with the historic results of 2022. We have managed to exceed the higher end of our guidance range both in operating revenues and in our CMO business. We have been able to deliver operating revenue growth of 26% in a difficult environment thanks to the strength of our contract manufacturing organization business, which continues to enjoy good sales prospects, and an EBITDA margin rise of 2.8pp, mainly as a result of the operating leverage contribution of our CMO business, the good performance of our enoxaparin biosimilar, and the recovery of the specialty pharma business. ROVI’s commitment to innovation is reflected in the figures of the full year 2022. We are in a new phase of growth and we expect our robust balance sheet to allow us to take advantage of other opportunities to expand our sales base and improve the utilization of our asset base”.*

OUTLOOK

For 2023, ROVI expects its **operating revenue to show low-double-digit negative growth** on 2022, although a **positive growth of between 5% and 10%** is expected in comparison with the 2021 figure.

For 2023, ROVI is assuming a new post-pandemic scenario in which COVID-19 would foreseeably be a seasonal disease and, in principle, the vaccine would be administered once a year. For this reason, ROVI expects a stronger second half of the year compared to the first half regarding the CMO business. The first quarter of 2023 is expected to include revenues linked to the production of vaccines in the fourth quarter of 2022 but the second quarter of 2023 is expected to be the lowest quarter in terms of CMO sales.

Nevertheless, the uncertainty related to the evolution of the disease is very high. It is not, therefore, possible to make a precise assessment of the impact that this new scenario could have on its CMO business. Likewise, under the terms of the agreement signed with Moderna in February 2022, ROVI is still investing in increasing the compounding, aseptic filling, inspection, labelling and packaging capacities at its facilities and expects them to be fully installed at the end of 2024.

Taking account of the aforementioned guidance on a decrease in operating revenue in 2023, as well as the fact that ROVI will continue with its investment policy as stated, it is reasonable to expect that the Company's profits may also see a downward adjustment in 2023.

R&D UPDATE

ISM® technology platform

Okedi® (Risperidone ISM®) is the first ROVI product based in its leading-edge drug delivery technology, ISM®. It is a novel investigational antipsychotic for the treatment of schizophrenia with once-monthly (every 28 days) injections which has been developed and patented by Laboratorios Farmacéuticos ROVI S.A. and which, as of the first injection, provides immediate and sustained plasmatic drug levels and does not require loading doses or supplementation with oral risperidone.

In January 2020, ROVI announced the commencement of the centralised procedure for registration of Okedi® with the European Medicines Agency (EMA). On 16 December 2021, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Okedi®. Finally, on 15 February 2022, the European Commission authorised the marketing of Okedi® (Risperidone ISM®) for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone, and it was launched in Germany in April 2022, in the UK in July 2022 and in Spain in September 2022.

Likewise, at its Capital Markets Day held on 24 November 2020, ROVI announced the filing of an NDA (New Drug Application), i.e. a registration dossier to obtain marketing authorisation in the USA, with the FDA (Food and Drug Administration). ROVI was informed of the delay in a decision on granting marketing authorisation for Risvan® (Risperidone ISM®) by the U.S. Food and Drug Administration ("FDA"). Furthermore, on 24 September 2021, ROVI received a Complete Response Letter from the FDA with outstanding questions on the Risvan® dossier, which were answered in January 2022. In the third quarter of 2022, the FDA issued a second Complete Response Letter, with some outstanding questions for ROVI and also with questions for one of its manufacturers. Both ROVI and the manufacturer provided answers to the FDA. The FDA has notified ROVI that the user fee goal date is 27 July 2023.

The grant of the marketing authorisation for Risvan® by the FDA is also subject to the closure of the observations issued by the FDA after the pre-approval inspection (PAI) of the plant where the product is manufactured (located in Madrid, Spain) that was conducted on the second half of June 2022. Responses to these observations were provided to the FDA and ROVI is awaiting the FDA's review of these responses and notification from the FDA as to whether or not a second inspection to ROVI's manufacturing plant is required to close the pending observations.

In addition, in January 2023 the FDA conducted the pending inspection of a supplier to close deficiencies found by the FDA in a process not related to Risperidone ISM®. As a

result of this inspection, the FDA has issued new observations and the manufacturer is currently estimating a time frame to provide the responses.

In addition, the company is continuing with the clinical development of Letrozole ISM®, which represents the second candidate using ROVI's ISM® technology platform. This new investigational medicine is, to the best of ROVI's knowledge, the first long-acting injectable aromatase inhibitor intended for the treatment of hormone-dependent breast cancer. ROVI has obtained positive results in phase I that confirm that this ISM® formulation provides a prolonged release of letrozole which produces a sustained suppression of oestrogenic hormones. These outstanding results allow ROVI to predict a superior oestrogen suppression compared to daily doses of oral Femara® (daily 2.5 mg doses) when Letrozole ISM® treatment starts with 100 mg doses at day 1 and week 8, followed by maintenance doses of 100 mg of Letrozole ISM® every 52 weeks. After several official interactions with the FDA, the company has been requested to perform a phase II clinical study in adult patients with HR+/HER- locally advanced or metastatic breast cancer, comparing Letrozole ISM® versus Femara®.

Lastly, ROVI's R&D team is progressing in the development of a new formulation of Risperidone for a 3-monthly injection, which would complement the current 4-weekly formulation of Risperidone ISM® for the maintenance treatment of patients with clinically stable schizophrenia. The regulatory toxicity studies needed to start the clinical development in humans have already been completed. The company is currently initiating all arrangements to conduct a phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of various candidate formulations at different dose strengths and injection sites; this study is planned to begin in the first half of 2023.

ESG

In July 2022, ROVI's ESG aspects were evaluated by Sustainalytics, a Global Leader in ESG & Corporate Governance, having obtained an "ESG Risk Rating 2022" of 17.3, which places the company at low risk (between 10 and 20). This rating improves by 1.1 points the one achieved in the previous year (18.4).

ROVI attains the first position out of 458 companies in the sub-industry "pharmaceuticals" and 22th out of a total of 970 companies in the "pharmaceutical industry", which includes biotech, pharmaceutical and laboratory equipment companies.

Among ROVI's basic action principles included in the Policy against Climate Change are the following:

- Reduction in greenhouse gas emissions.
- Reduction in non-greenhouse gas emissions, improving the air quality.
- Carbon neutrality, reducing emissions and offsetting those that cannot be avoided.
- Use of renewable energies, increasing the consumption thereof until the total energy consumed comes from renewable sources. The origin of 100% of the electrical energy used in our facilities is renewable.

ROVI, as a member of the United Nations Global Compact, upholds, by adopting and disseminating it, the inclusion of the principles of this Compact, as well as other international instruments, especially in the spheres of human rights, workplace practices, the environment and the fight against corruption.

Likewise, ROVI monitors the ESG aspects evaluated by MSCI, a rating agency highly valued among the investment community, obtaining an "A" rating since 2021^(*). MSCI ESG Research provides ESG ratings on companies on a scale from AAA ("Leader") to CCC ("Laggard"), based on their exposure to and ability to manage industry-specific ESG risks relative to their comparable companies.

(*)THE USE BY ROVI OF ANY MSCI ESG RESEARCH LLC OR ITS AFFILIATES ("MSCI") DATA, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT, RECOMMENDATION, OR PROMOTION OF ROVI BY MSCI. MSCI SERVICES AND DATA ARE THE PROPERTY OF MSCI OR ITS INFORMATION PROVIDERS, AND ARE PROVIDED 'AS-IS' AND WITHOUT WARRANTY. MSCI NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI.

KEY OPERATING AND FINANCIAL EVENTS

ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® in the United States

ROVI informed (by publication of the relevant information number 20446 dated 16th of February 2023) on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States and reported that it has now filed the final responses to the Complete Response Letter received from the United States Food and Drug Administration (FDA) in the third quarter of 2022. These responses likewise included the answers of one of ROVI's suppliers to outstanding questions.

The FDA has notified ROVI that the user fee goal date is 27 July 2023.

Likewise, ROVI has now filed the final report on correction of the deficiencies noted when the FDA inspected its facilities in June 2022. The evaluation of these corrections, as well as the notification as to whether the FDA will need to reinspect the ROVI facilities, is expected within the period ending on the user fee goal date.

Furthermore, in January 2023, the FDA carried out a pending inspection of a ROVI supplier. As a result of the inspection, the FDA issued a series of observations to said supplier, which the latter is working to answer. The time frame for the supplier's response will depend on how the FDA evaluates the observations issued.

Thus, ROVI is continuing with the roadmap that it notified in the presentation of the update of its strategy at its 2022 Capital Markets Day and will continue to report on the milestones deemed relevant in the process to obtain authorisation of Risvan® from the FDA as the timeline for registration in the United States advances.

Glicopepton Biotech founded to produce compounds of high technological value

ROVI announced (by publication of the relevant information number 18544 dated 4th of October 2022) that it presented with Càrniques Celrà, S.L. and Grupo Empresarial Costa, S.L., Glycopepton Biotech, S.L., a joint venture that involves the creation of one of the first national structures for self-sufficiency in heparins and products of high nutritional value to be used in the composition of animal feed and fertilisers. The goals of this project focus on transforming the present livestock production process into a high-value-added technological process based on a circular economy model.

The project involves the construction of a facility at the Industrial Logistics Platform of Fraga (Huesca), which will produce compounds of high biological value that derive from the intestinal mucosa of pigs. It will involve a joint investment of approximately 40 million euros over the next four years and is expected to create around 30 direct skilled jobs. The project will be subject to obtaining the applicable administrative and regulatory permits and authorisations.

Glicopepton Biotech combines ROVI's experience as a leading company in the research into low-molecular-weight heparins (LMWH) with the track records of Càrniques Celrà and Grupo Empresarial Costa, two major companies in the livestock and meat industry in Spain. LMWHs are anticoagulant drugs used to prevent and treat venous thromboembolic disease. They are a biological product whose raw material is obtained from the intestinal mucosa of pigs. This project seeks both the creation of economic and technological value, transforming pig mucosa into a high-value-added product like heparin, and the development of new animal food supplements and fertilisers.

ROVI has in-house production capacity to transform raw heparin into sodium heparin and intends to expand this capacity through the construction of a new sodium heparin production line (already underway), in order to be present in all the manufacturing phases of low-molecular-weight heparins.

Juan López-Belmonte Encina, ROVI's chairman and chief executive officer, highlighted "the strategic importance for Spain of a project with these characteristics, since it provides the country with the capacity to be self-sufficient in obtaining a raw material that is indispensable for the production of an essential medicine like low-molecular-weight heparins. At ROVI, we are very excited about this project since, as a company specialised in these medicines, it will enable us to take a further step in the vertical integration of our LMWH manufacturing."

ROVI Share Buy-back Programme

ROVI announced (by publication of the inside information number 1308 dated 22 February 2022) the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022.

End of the share buy-back programme

ROVI informed that, on 22 February 2022, the Board of Directors resolved to finalize the share buy-back programme launched by the Company as of 3 November 2021, having acquired 1,492,108 own shares, this is, 89% of the maximum number of shares to be acquired under the buy-back programme.

Launching of a new share buy-back programme

ROVI further informed that the Company launched, effective as of 23 February 2022, a new share buy-back program (the "Buy-back Program"), in accordance with the following terms:

- (i) Purpose and scope: the Buy-back Program's purpose is to redeem own shares of ROVI (share capital reduction) and, at the same time, to contribute to ROVI's shareholders remuneration by increasing earnings per share.
- (ii) Term: from 23 February 2022 and for a period of 6 months.
- (iii) Maximum monetary amount: up to 46,000,000 euros.
- (iv) Maximum number of shares to be acquired: 560,700 shares of the Company, representing approximately 1% of the Company's share capital as of the launch date of the programme.
- (v) Trading volume to be considered as reference: the trading volume to be taken as a reference for the purposes of the provisions of article 3.3 of Delegated Regulation 2016/1052 for the entire duration of the Buyback Program shall be 25% of the average daily volume of ROVI's shares on the Continuous Market of the Spanish Stock Exchanges during the twenty trading days prior to the date of the purchase.

On 29 March 2022, ROVI informed of the finalization of this second buy-back programme. The Company had acquired 560,700 treasury shares, this is, 100% of the maximum number of shares foreseen under the buy-back programme.

The purpose of the two buy-back programmes was to cancel treasury shares held by ROVI (by reducing the capital). The reduction of the capital through cancellation of 2,052,808 shares repurchased within the framework of the aforementioned buy-back programmes was approved at the General Shareholders' Meeting of 14 June, 2022 and executed by entering the pertinent deed of capital reduction into public record. The deed has inscribed at the Madrid Companies Registry and the new amount of the share capital, after the shares mentioned have been cancelled and excluded from trading, has appeared in the registers of the National Securities Market Commission and Iberclear.

Moderna and ROVI expand long-term collaboration for the manufacture of mRNA medicines over the next ten years

ROVI announced (by publication of the inside information number 1299 dated 16th of February of 2022) a long-term collaboration with Moderna to increase capacities for the compounding, aseptic filling, inspection, labelling, and packaging of ROVI's facilities located in Madrid, San Sebastián de los Reyes and Alcalá de Henares.

This new agreement, which has a term of ten years, includes a series of investments expected to allow the manufacturing capacity to increase across ROVI's facilities in Madrid, Spain. In addition to producing Moderna's COVID-19 vaccine, ROVI's platform could also be utilized to service future Moderna mRNA vaccine candidates.

"ROVI has been a pivotal partner in supporting the manufacturing of our COVID-19 mRNA vaccine for countries outside of the U.S., and this long-term agreement expands our partnership and allows for further scale-up for future mRNA medicines," said Juan Andres, Moderna's Chief Technical Operations and Quality Officer.

Mr. Juan López-Belmonte Encina, ROVI's Chairman and Chief Executive Officer, said: "We are delighted to expand our collaboration with Moderna and become a long-term manufacturing partner. At ROVI we are working to contribute all our experience as a high-technological-value contract manufacturer of injectables to the solution of this pandemic and we are confident of our ability to take part in the manufacturing of new mRNA candidates in the future."

ROVI receives the European Commission's approval of Okedi® as a treatment for schizophrenia

ROVI announced (by publication of the relevant information number 14055 dated 15th of February of 2022) that the European Commission had authorised the marketing of Okedi® (Risperidone ISM®) for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone, since, as of the first injection, it provides immediate and sustained plasmatic drug levels and does not require loading doses or supplementation with oral risperidone.

This approval is based on the positive results of the pivotal PRISMA-3 study on the efficacy and safety of Risperidone ISM® in schizophrenia patients². The results obtained in this study show that the two different doses (75 mg and 100 mg once a month) have achieved the prespecified primary and secondary efficacy endpoints for treatment of patients with acute exacerbation of schizophrenia. The primary efficacy endpoint, the PANSS total score (mean difference, CI: 95%), improved significantly with Risperidone ISM® 75 mg and 100 mg from the beginning until day 85, with adjusted differences of -13.0 (17.3 to -8.8; $p < 0.0001$) and -13.3 (-17.6 to -8.9; $p < 0.0001$), respectively. Significantly improved mean changes for the secondary endpoint, the CGI-S score, were also obtained for Risperidone ISM® in comparison with the placebo, -0.7 (-1.0 to -0.5; $p < 0.0001$), for both doses. The significant statistical improvement for both efficacy results was observed as early as 8 days after the first injection. The most frequently reported treatment-emergent adverse events were increased blood prolactin (7.8%), headaches (7.3%), hyperprolactinemia (5%) and weight increase (4.8%). No important new or unexpected safety information was reported. Likewise, patients who successfully completed the double-blind period were offered the opportunity to continue in a long-term, open-label

² Correll, C.U., Litman, R.E., Filts, Y. et al. Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation. *npj Schizophr* 6, 37 (2020). <https://doi.org/10.1038/s41537-020-00127-y>

12-month extension phase with once every four weeks injections of Risperidone ISM® (75 mg or 100 mg). New, clinically stable patients ("de novo" patients) were also able to enter this open phase of the study. Long-term treatment was observed to be effective, safe and well tolerated in adult patients with schizophrenia, regardless the initial severity of the disease or whether they had been treated previously with Risperidone ISM® during an acute exacerbation or switched from stable doses of oral risperidone³.

"We are very excited about the European Commission's approval of Risperidone ISM® because we think our medicine will be able to contribute to the clinical management of schizophrenia patients. Likewise, we have launched the product in Germany, United Kingdom and Spain", commented Juan López-Belmonte Encina, ROVI's Chairman and Chief Executive Officer.

Regarding other territories, ROVI filed the application for marketing authorisation of Risperidone ISM® with the United State Health authorities, the U.S. Food and Drug Administration ("FDA") on 24 November, 2020 and the dossier is currently being reviewed by the FDA.

About ROVI

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, already present in more than 60 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its Enoxaparin biosimilar, developed in-house, in Europe and it is already marketed in 38 countries. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es.

For further enquiries, please contact:

Juan López-Belmonte Encina
Chairman and Chief Executive Officer
www.rovi.es

Javier López-Belmonte Encina
Deputy Chairman and Chief Financial Officer
www.rovi.es

³ Filts Y, Litman RE, Martínez J, Anta L, Naber D, Correll CU. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. *Schizophr Res.* 2021 Nov 27;239:83-91.

Marta Campos Martínez
Head of Investor Relations
+34 912444422
mcampos@rovi.es
www.rovi.es

Beatriz de Zavala Mazarredo
Investor Relations Analyst
bdezavala@rovi.es
www.rovi.es

Forward-looking statements

This news release contains forward-looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance, or achievements of ROVI or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward looking statements. The statements in this press release represent ROVI's expectations and beliefs as of the date of this press release. ROVI anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ROVI's expectations or beliefs as of any date after the date of this press release.

Alternative performance measures

This press release may include certain Alternative Performance Measures (“APMs”) not prepared under IFRS-EU and not reviewed or audited by either the Company’s auditors or an independent expert. Furthermore, the way in which the Group defines and calculates these measures may differ from the way in which other companies calculate similar measures. Consequently, they may not be comparable.

APPENDIX 1

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2022 AND DECEMBER 31, 2021

IN € THOUSANDS	December 31, 2022	December 31, 2021
ASSETS		
Non-current assets		
Property Plant and Equipment	215,541	181,775
Intangible assets	35,744	38,558
Investment in a joint venture	2,193	1,994
Deferred income tax assets	2,078	3,850
Equity securities	9	72
Financial receivables	65	65
	255,630	226,314
Current assets		
Inventories	311,944	245,473
Trade and other receivables	180,011	150,172
Current income tax assets	4,148	9,891
Prepaid expenses	2,025	1,791
Cash and cash equivalents	124,945	99,035
	623,073	506,362
Total assets	878,703	732,676

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2022 AND DECEMBER 31,
2021

IN € THOUSANDS	December 31, 2022	December 31, 2021
EQUITY		
Equity attributed to the company	520,012	470,976
Share capital	3,241	3,364
Share premium	87,636	87,636
Legal reserve	673	673
Treasury shares	(27,561)	(66,121)
Retained earnings and voluntary reserves	256,362	292,349
Profit for the year	199,669	153,077
Accumulated other comprehensive income	(8)	(2)
Non-controlling interests	1,367	–
Total equity	521,379	470,976
LIABILITIES		
Non-current liabilities		
Financial debt	59,441	66,745
Deferred income tax liabilities	677	776
Contract liabilities	1,545	1,460
Deferred income	1,774	2,331
	63,437	71,312
Current liabilities		
Financial debt	12,725	6,417
Trade and other payables	165,776	125,173
Current tax liabilities	–	681
Contract liabilities	114,901	57,632
Deferred income	485	485
	293,887	190,388
Total liabilities	357,324	261,700
Total equity and liabilities	878,703	732,676

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS FOR 2022 AND 2021

IN € THOUSANDS	2022	2021
Revenue	817,698	648,677
Changes in inventories of finished goods and work in progress	38,883	782
Raw materials and consumables used	(339,824)	(264,637)
Work carried out by the Group on non-current assets	2,856	–
Employee benefit expenses	(106,522)	(89,803)
Other operating expenses	(136,482)	(93,502)
Amortisation and depreciation	(22,871)	(21,364)
Impairment of non-current assets	(2)	(95)
Recognition of government grants on non-financial non-current assets and other	2,112	1,334
Share of profits of joint venture	199	182
OPERATING PROFIT (EBIT)	256,047	181,574
Finance income	1,770	68
Finance costs	(849)	(905)
Impairment and gain or loss on measurement of financial instruments	1,820	2,069
Exchange difference	(821)	(178)
FINANCE INCOME/(COSTS) - NET	1,920	1,054
PROFIT BEFORE INCOME TAX	257,967	182,628
Income tax	(58,302)	(29,551)
PROFIT FOR THE YEAR	199,665	153,077
Net profit attributable to parent company	199,669	153,077
Profit attributable to minority interests	(4)	–

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED CASH FLOW STATEMENTS FOR 2022 AND 2021

IN € THOUSANDS	2022	2021
Cash flows from operating activities		
Profit before tax	257,967	182,628
Adjustments for non-monetary transactions:		
Amortisation and depreciation	22,871	21,364
Finance income	(1,770)	(68)
Valuation allowance	5,160	4,885
Adjustments for changes in value of derivatives	11	(908)
Gain or loss on derecognition of financial assets and liabilities	(1,831)	(1,161)
Exchange differences	821	-
Finance expenses	849	905
Grants, distribution licenses and other deferred income	(2,904)	(6,473)
Other current assets (prepaid expenses)	(234)	(1,778)
Share of profit in joint venture	(199)	(182)
Share-based payments	-	1,403
Changes in working capital:		
Trade and other receivables	(26,820)	(74,187)
Inventories	(71,591)	(23,427)
Trade and other payables	41,672	35,358
Other collections and payments:		
Proceeds from contract manufacturing services	57,104	34,429
Proceeds from distribution licenses	385	518
Interest paid	-	(4)
Income tax cash flow	(43,889)	(23,861)
Net cash generated from (used in) operating activities	237,602	149,441
Cash flows from investing activities		
Purchases of intangible assets	(669)	(722)
Purchases of property, plant and equipment (usage rights not included)	(50,719)	(40,218)
Proceeds from sale of property, plant and equipment	78	33
Purchases of other financial assets	(5,870)	-
Proceeds from sale of other financial assets	20	-
Interest received	6	68
Net cash generated from (used in) investing activities	(57,154)	(40,839)
Cash flows from financing activities		
Repayments of financial debt	(6,768)	(6,192)
Proceeds from financial debt	1,399	1,340
Interest paid	(291)	(288)
Purchase of treasury shares	(177,008)	(78,785)
Reissue of treasury shares	77,766	42,328
Dividends paid	(51,007)	(21,132)
Capital contribution to subsidiaries	1,371	-
Net cash generated from (used in) financing activities	(154,538)	(62,729)
Net (decrease) increase in cash and cash equivalents	25,910	45,873
Cash & cash equivalents at the beginning of the year	99,035	53,162
Cash and cash equivalents at the end of the year	124,945	99,035